FK506-induced intractable leukoencephalopathy following allogeneic bone marrow transplantation.
FK506-related leukoencephalopathy has been reported to be reversible and readily treated by discontinuation or reduction of FK506. We describe two pediatric cases of FK506-related leukoencephalopathy following allogeneic bone marrow transplantation, which could not be readily controlled. These cases show that FK506-related leukoencephalopathy is not always reversible, and patients may develop epilepsy. Bone Marrow Transplantation (2000) 25, 331-334.
Misawa
A
A
Department of Pediatrics, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Takeuchi
Y
Y
Hibi
S
S
Todo
S
S
Imashuku
S
S
Sawada
T
T
D000208:Acute Disease; D000293:Adolescent; D002675:Child, Preschool; D016572:Cyclosporine / Q000009:adverse effects; D015140:Dementia, Vascular / Q000139:chemically induced* / Q000473:pathology; D004569:Electroencephalography; D005260:Female; D006086:Graft vs Host Disease / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000628:therapy; D007951:Leukemia, Myeloid / Q000150:complications / Q000628:therapy; D008279:Magnetic Resonance Imaging; D008297:Male; D012640:Seizures; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects*
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus